Nat Commun 2021 Feb 8;12(1):995. Epub 2021 Feb 8.
Department of Biostatistics and Data Science, Division of Public Health Sciences, Wake Forest University School of Medicine, Winston-Salem, NC, USA.
Diabetes Technol Ther 2021 Sep 15. Epub 2021 Sep 15.
Endocrinology & Diabetes Specialists of Northwest Ohio, Findlay, Ohio, United States;
Objective: Use of real-time CGM (rtCGM) has been shown to improve glycemic control in patients with type 2 diabetes (T2D) who are treated with intensive insulin therapy. However, most T2D patients are denied coverage for rtCGM due to failure to meet payer eligibility requirements: treatment with ≥3 insulin injections (or pump) and history of 4x/day blood glucose testing. We investigated the relevance of these criteria to successful rtCGM use. Read More
Clin Toxicol (Phila) 2021 Sep 15:1-3. Epub 2021 Sep 15.
St Vincent's Clinical School, University of New South Wales, Darlinghurst, NSW, Australia.
Introduction: High dose insulin (HDI) therapy for cardiogenic shock from acute poisoning can be complicated by treatable hypoglycemia which persists following poisoning recovery. Glucose requirements post-HDI reflect supraphysiological insulin plasma concentration. A publication reported a patient treated with HDI with plasma insulin concentrations >1000 µU/mL and elimination half-life 10-18 h requiring intravenous glucose replacement for >5 days. Read More
Atherosclerosis 2021 Sep 9;335:16-22. Epub 2021 Sep 9.
Division of Endocrinology and Metabolism. Director, Alberta Diabetes Institute. Charles A. Allard Chair in Diabetes Research. University of Alberta, 1.005 Li Ka Shing Centre for Health Research Innovation Edmonton, AB, T6G 2E1, Canada. Electronic address:
Diabetes is a major risk factor for cardiovascular (CV) disease. In contrast to the clear benefits from treatments which reduce blood pressure and lipids, clinical trials targeting blood glucose have not shown clear CV benefits. Interventions to intensify glycemic control early in the course of diabetes may have benefits in long term observational studies (DCCT-EDIC/UKPDS), but may not be helpful if introduced late in the course of type 2 diabetes (ACCORD, ADVANCE, VA-DT). Read More
J Coll Physicians Surg Pak 2021 Sep;31(9):1081-1084
Department of Pediatric Medicine, Jinnah Medical & Dental College, Karachi, Pakistan.
Objective: To determine the variations in peak growth hormone levels during insulin tolerance test (ITT) in diagnosis of growth hormone deficiency (GHD) in children presenting with short stature.Study Design: Descriptive study.Place And Duration Of Study: Department of Pediatric Endocrinology, National Institute of Child Health (NICH), from January to December 2018. Read More
Diabetes Metab J 2021 Sep 9. Epub 2021 Sep 9.
Division of Endocrinology and Metabolism, Department of Internal Medicine, Research Institute of Clinical Medicine of Jeonbuk National University Medical School-Biomedical Research Institute of Jeonbuk National University Hospital, Jeonju, Korea.
Background: It is unclear whether glycemic variability (GV) is a risk factor for diabetic peripheral neuropathy (DPN), and whether control of GV is beneficial for DPN. The purpose of this study was to investigate the effect of GV on peripheral nerve damage by inducing glucose fluctuation in streptozotocin-induced diabetic rats.Methods: Rats were divided into four groups: normal (normal glucose group [NOR]), diabetes without treatment (sustained severe hyperglycemia group; diabetes mellitus [DM]), diabetes+once daily insulin glargine (stable hyperglycemia group; DM+LAN), and diabetes+once daily insulin glargine with twice daily insulin glulisine (unstable glucose fluctuation group; DM+Lantus [LAN]+Apidra [API]). Read More